Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. The implant sends continuous glucose sensing data to a transmitter device attached to the patient’s skin with a silicone adhesive. This transmitter then sends the data to a mobile app, where the patient can evaluate their glucose levels and take action.
Through this partnership, Senseonics and Welldoc plan to deliver a next-generation app that maintains all existing features from which patients currently benefit, alongside new features to enhance user experience and facilitate better integration with popular digital health tools.
Senseonics and Welldoc plan to have the app facilitate seamless integration with Apple Health and Google Health Connect. This feature would enable users to compile their valuable health and fitness data into one place. Where available, the app will also continue to support the combination of Eversense 365 and the Sequel Med Tech twiist automated insulin delivery system. Senseonics and Sequel launched the pairing earlier this year.
The companies say users can expect a revamped app interface with improved visual components and workflows for all features. They specifically aim to enhance the user interface and experience of sensor and transmitter integration. That includes pairing and activation, communication status, synchronization, data displays and alerts.
Senseonics expects the new app to launch in the U.S. in the second half of 2026. It anticipates European availability early next year. Once they launch the new app, Senseonics and Welldoc expect to work together on a cadence of future app releases. The apps leverage Welldoc’s established AI-powered platform and could eventually include CGM-informed bolus calculation, medication management, metabolic tracking and logbook and educational resources.
Commentary from Senseonics and Welldoc officials
Tim Goodnow, CEO at Senseonics, said:
“At Senseonics we’re committed to making the CGM experience as convenient and effective as possible, with excellence at the heart of everything we do. This makes Welldoc a natural partner for developing our next-generation app and we look forward to leveraging their platform and expertise in AI-powered digital health. Eversense 365 has an exceptional track record of customer satisfaction, and we are always listening to patients so that we can improve the user experience. Our app will now evolve to make living with diabetes even easier, with better functionality, new features and enhanced integration with the digital health ecosystem.”
Kevin McRaith, CEO and president of Welldoc, added:
“We are pleased to enter this partnership with Senseonics, which brings together two companies that are resolutely focused on improving patient experience and outcomes in chronic care. Eversense 365 is highly advanced technology that deserves an app to match its unique patient proposition and disruptive potential. The new app will benefit from Welldoc’s deep domain expertise, healthcare-ready AI capabilities and broader digital health platform, to offer patients a best-in-class user experience and better interoperability with popular health tools.”
